CagriSema Demonstrates Superior HbA1c Improvement and Weight Loss in Latest Clinical Trial

Novo Nordisk’s dual-therapy formulation, CagriSema, has outperformed single-agent semaglutide across key efficacy measures in the REIMAGINE 2 trial. The combination therapy, which pairs a long-acting GLP-1 receptor agonist with cagrilintide (an amylin receptor agonist), revealed compelling results at the 68-week mark, marking a significant advancement in type 2 diabetes treatment options.

Clinical Efficacy: HbA1c Reduction Meets Weight Management Goals

The trial data showcases CagriSema’s dual-benefit approach. At week 68, the combination therapy achieved a 1.91%-point reduction in HbA1c—a critical marker of blood glucose control—alongside an impressive 14.2% weight loss across all dosage levels tested. These improvements exceeded what either component achieved individually, underscoring the synergistic value of the two-drug approach.

The mechanism combines two complementary pathways: semaglutide addresses glucose regulation through GLP-1 signaling, while cagrilintide enhances satiety and metabolic control through amylin receptor activation. This combination approach targets multiple biological pathways simultaneously, potentially offering patients more comprehensive metabolic management.

Safety Profile and Treatment Application

In the 68-week efficacy and safety evaluation, CagriSema exhibited a favorable tolerability profile consistent with GLP-1 and amylin-based therapies. The compound is being investigated as both a weight-management solution under the REDEFINE programme and as a diabetes treatment through the REIMAGINE clinical development programme.

The company recently submitted CagriSema for weight management to the US FDA in December 2025, building on pivotal data from the REDEFINE 1 and REDEFINE 2 trials. Following positive readouts from REIMAGINE 1 and REDEFINE 3, Novo Nordisk plans to engage with regulatory authorities to establish the approval pathway for the diabetes indication.

Strategic Outlook and Market Implications

Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, highlighted the clinical significance: “By combining semaglutide and cagrilintide, we’re achieving superior outcomes in both HbA1c control and weight reduction beyond what individual therapies deliver. This positions CagriSema as potentially the first amylin-based combination option for type 2 diabetes patients prioritizing weight loss alongside glucose management.”

Detailed REIMAGINE 2 results are expected at a major scientific conference in 2026. Market response to the announcement was cautiously positive, with Novo Nordisk shares trading near steady levels following the headline results release.